Collagen-povidone for Diabetic Seniors' Tenosynovitis
- Conditions
- Diabetes Complications
- Interventions
- Drug: collagen-povidone solution
- Registration Number
- NCT06396819
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Brief Summary
Diabetes affects 415 million adults globally, leading to hand issues. Povidone collagen shows promise in managing tenosynovitis. A clinical trial was conduced to compared its efficacy in adults over 60. It is shown that the intervention reduces pain, improves functionality, and grip strength with no complications. Collagen povidone holds potential for treating diabetic hand issues.
- Detailed Description
A randomized clinical trial from January 2022 to January 2023 compared povidone collagen intervention with a placebo in adults aged 60 and above suffering from stenosing tenosynovitis. Participants were randomized into Case (collagen-povidone) and Control (physiological solution) groups. The study evaluated parameters like tenosynovitis, diabetes, pain, functionality, and grip strength.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
- Diagnostic of stenosing tenosynovitis
- Diagnostic of diabetes
- Adults aged 60 or older
- Adults aged 60 or older
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Therapeutic intervention using povidone collagen collagen-povidone solution - Therapeutic intervention using placebo collagen-povidone solution -
- Primary Outcome Measures
Name Time Method Mean evolution time of tenosynovitis 12 months Tenosynovitis should decreased its progression in the experimental group
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Unidad de Investigación Biomédica 02, Unidad Médica de alta especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico
🇲🇽Guadalajara, Jalisco, Mexico